Summary
12.42
-0.01
(-0.08%)
07/17/2026
COMPASS Pathways plc (CMPS)Key Facts
Performance
Historical returns1D
-0.08%
1W
-8.87%
1M
8.18%
3M
86.64%
6M
69.12%
1Y
216.28%
5Y
-64.51%
Snapshot
Key statisticsClose
12.42
Change
-0.01
Change %
-0.08%
Open
12.41
Day Range
12.02 – 13.04
Volume
6,440,445
Avg Vol (20d)
4,618,232
Rel Vol
1.39x
52W Range
3.83 - 15.40
vs 52W High
-19.35%
vs 52W Low
224.28%
Gap
1.08
Market Cap
USD 536.65M
Beta
2.23
Price Chart
Advanced chartCompareLast 730 data points are shown. To view all data, Upgrade to PRO plan!
New Highs
Historical highs| Period | New Highs | From Last |
|---|---|---|
| 5-Day | 1× | -7.24% |
| 1-Month | 6× | -17.58% |
| 3-Month | 12× | -17.58% |
| 6-Month | 15× | -17.58% |
| YTD | 16× | -17.58% |
| Period | New Highs | From Last |
|---|---|---|
| 52-Week | 33× | -17.58% |
| 2-Year | 15× | -17.58% |
| 3-Year | 12× | -17.58% |
| 5-Year | 10× | -74.63% |
| 10-Year | n/a | n/a |
Financial SnapshotFY 2025
Full financialsRevenue
n/a
Net Income
-USD 287.86M
+85.6% YoY
EPS
-3.08
+33.9% YoY
Gross Margin
n/a
Operating Margin
n/a
Net Margin
n/a
EBITDA
-USD 285.60M
Free Cash Flow
-USD 157.24M
ROE
544.7%
ROA
-136.8%
Debt / Equity
-0.40x
net debt -USD 128.68M
Cash & Equiv.
USD 149.61M
Fundamental Ratings
MainC+
RecommendedSell
DCFNeutral
ROEStrong Sell
ROAStrong Sell
Debt/EquityBuy
P/EStrong Sell
P/BNeutral
Latest Earnings
- CMPS reported last earnings on 2026-05-13.
- EPS of $-0.3 vs $-0.45 estimated — surprise $0.15.
- Revenue of $0M vs $0M estimated — surprise $0M.
News
All newsCompass Pathways gains Jefferies support as COMP360 data distinguishes psychological support from psychotherapy
Compass Pathways (NASDAQ:CMPS)'s COMP360 treatment model may face fewer regulatory hurdles as new Phase II analysis distinguishes the company's psychological support approach from psychotherapy, Jefferies analysts have highlighted. In a note reviewing a post-hoc analysis of Compass Pathways...
Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc analysis of support methods used in an open-label...
Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies
Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could...
CleanSpark shares surge after company secures $6.6B data center lease agreement
CleanSpark Inc (NASDAQ:CLSK) shares surged more than 12% after the company announced a 20-year lease agreement for its Sandersville, Georgia data center...
Tower Semiconductor shares jump as company announces Japan expansion to boost silicon photonics capacity
Tower Semiconductor (NASDAQ:TSEM) shares rose 13% on Tuesday after the company announced a strategic expansion of its silicon photonics, silicon germanium...
Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up
Compass Pathways NASDAQ: CMPS said new 26-week data from its Phase 3 COMP006 trial further support the durability and safety profile of COMP360, its investigational psilocybin therapy for treatment-resistant depression, as the company works toward a potential U.S. launch in the first half of 2027.
Compass Pathways: 'Strong Buy' COMP360 Trial Wins And Q4 NDA Full Submission
Compass Pathways: 'Strong Buy' COMP360 Trial Wins And Q4 NDA Full Submission
COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression Transcript
COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression Transcript
Compass Pathways Highlights Long-Term Data from Resistant Depression, Backs 2027 Launch Timeline
Compass Pathways plc (NASDAQ:CMPS) on Wednesday reported 26-week results from Part B of its Phase 3 COMP006 trial, reinforcing the rapid and durable efficacy of COMP360, its synthetic psilocybin therapy for treatment-resistant depression (TRD).
Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the 26-week results (Part B) from its second ongoing Phase 3 COMP006 trial of COMP360, a...
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026...
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
Issued on behalf of Helus Pharma™ Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., says its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder has surpassed 86% enrollment, keeping the FDA Breakthrough-designated...
Compass Pathways Elects Kathleen Tregoning to Board of Directors
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual...
Compass Pathways: A Trip Worth Taking Before The FDA Verdict
COMPASS Pathways (CMPS) is positioned to pioneer COMP360, the first psychedelic drug for treatment-resistant depression (TRD), with expected FDA approval later this year. COMP360 demonstrated primary endpoint success in Phase 3 trials, with potential for less frequent dosing and improved...
Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins
Compass Pathways NASDAQ: CMPS executives said the company remains on track to target a fourth-quarter New Drug Application filing for COMP360, its synthetic psilocybin treatment candidate for treatment-resistant depression, while preparing commercially for a potentially accelerated regulatory...
Compass Pathways: Imminent Commercialization Should Provide Further Upside
Compass Pathways is nearing an inflection point, with solid Phase III data and government support pointing towards a likely FDA approval. CMPS is positioned to address the large, underserved treatment-resistant depression market, leveraging regulatory tailwinds and growing psychiatric support for...
Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced